• Slide1

Profiling your product through the complex multidimensional relationships between
exposure, biological response, and human health outcome

News

News

How Does It Work

How Does It Work

For A Safer Future

For A Safer Future

Still on the table

Still on the table

  • Banner1

Breaking news

  • The Interreg. project Herinneringen ('Memories') 2018 Symposium on early biomarkers for sporadic Alzheimers

    The Interreg. project Herinneringen ('Memories') 2018 Symposium on early biomarkers for sporadic Alzheimers

    27.11.2018 by ToxGenSolutions BV

    Many thanks to the participants, and especially the speakers: Catherine Verfaillie (KULeuven (host)), Francesca Pistollato (EURLECVAM (invited speaker)), Annemie Ribbens (icometrix), Sebastiaan Engelborghs (UAntwerpen), Gerard Griffioen (reMYND), Jacco Briede and Rob Schlooz (UMaastricht) and Erwin L Roggen (ToxGenSolutions).

    The presentations will soon be available on toxgensolutions.eu.

  • ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

    ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

    16.11.2018 by ToxGenSolutions BV

    Position for an experienced researcher

    ToxGenSolutions BV invites applications for a position as experienced researcher, starting January 1, 2019.

    You see you self as a researcher at a spin-off company based at the University of Maastricht with an ambition to expand. The research field is Neurodegeneration of the human brain, with focus on Alzheimer’s Disease (AD).

    The successful candidate will participate in an AD project supported by EU Interreg. Vlaanderen – Nederland, het Nederlands Ministerie van Economische Zaken, de Provincie Nederlands Limburg, Vlaams Agentschao Innoveren en Ondernemen (VLAIO) and the Provinces of Antwerpen and Vlaams Brabant.

    Responsibilities and tasks:

    - Experimental planning of the project, problem solving and assuring compliance with the timelines of the project.

    - Laboratory work within the field of microRNA detection.

    - Performance of differential (epi-)genomics and pathway analyses.

    - Handling and reporting of experimental data.

    - Preparing microRNA profiles with diagnostic value for the market.

    Qualifications:

    Applicants should have a PhD degree in (epi)genomics or equivalent with several years of experience.

    The profile of the ideal candidate:

    - You have experience with and enjoy laboratory work.

    - You have hands-on experience with state-of-the-art (epi-)genomics technologies.

    - Experience in bioinformatics will be considered an advantage.

    - You communicate fluently in English.

    - You can work with deadlines and pressure.

    - You are flexible, enthusiastic and responsible, with team spirit and excellent collaboration skills.

    We offer:

    ToxGenSolutions BV offers a competitive scientific environment with the ambition to build a self-sustainable company applying front-edge non-animal toxicogenomics approaches on human health problems to provide the customer with genetic biomarker fingerprints for application in novel more accurate methods for diagnosis, novel tools for follow-up of disease progression or response to treatment in humans, and novel drug development.

    Salary and terms of employment:

    The appointment will be based on the current wage scales that are applied by the University of Maastricht. The position is for two years.

    Further information:

    For additional information about the position, please contact Erwin L Roggen (Denne e-mail adresse bliver beskyttet mod spambots. Du skal have JavaScript aktiveret for at vise den.).

    You can read more about ToxGenSolutions BV on www.toxgensolutions.eu.

    Application procedure:

    Please submit your application no later than December 10, 2018 (Local time). Applications and enclosures received after the deadline will not be considered.

    Applications must be submitted as one PDF file containing all your materials in English. The file must include:

    - Application (cover letter)

    - CV

    - Diploma (MSc)

    All interested candidates irrespective of age, gender, disability, race, religion or ethnic background are encouraged to apply.

  • You are hereby cordially invited to the first annual meeting on November 23th 2018 in building ON1 at the katholieke University Leuven (Herestraat 49, Leuven).

    You are hereby cordially invited to the first annual meeting on November 23th 2018 in building ON1 at the katholieke University Leuven (Herestraat 49, Leuven).

    23.10.2018 by ToxGenSolutions BV

    The project ‘Herinneringen’ (‘Memories’) is about to finish the first year of its search for a cost-effective and minimally invasive method allowing for accurate diagnosis of (sporadic) Alzheimer’s disease (AD) before significant damage to the brain has occurred. You are hereby cordially invited to the first annual meeting on November 23th 2018 in building ON1 at the katholieke University Leuven (Herestraat 49, Leuven). Participation is free but registrations via the project web site (Menu, Contact) is required for practical reasons. The program can be downloaded from the same web site. Francesca Pistollato from the European Reference Laboratory – European Center for validation of Alternative methods to Animal Testing (EURL-ECVAM) will address the current challenges met by traditional AD research, and the need for the paradigm shift that forms the basis of the project ‘‘Herinneringen’ (‘Memories’). The project partners will present an overview of the different activities that are planned to meet the final goal, and progress will be reported where relevant. Special attention will be given to (i) the selection of the external risk factors for sporadic AD; (ii) the cell-based methods for identification of molecular and cellular processes that may be involved in the onset and early development of AD-related processes; (iii) the strategies to scientifically validated the human relevance of the identified potential biomarkers. See you November 23th.

  • First newsletter of the Project ''Herinneringen'' is available

    First newsletter of the Project ''Herinneringen'' is available

    Private-public funded innovation looking at Alzheimer’s disease initiation and development in a different way Newsletter: Interreg. Project ‘Herinneringen’ (''Memories''), Issue 1, 07.2018 (https://herinneringen.eu/en)
  • @ToxGenSolutions BV disembarks on its data-driven journey towards novel tools and treatments for improving the quality of life of patients with sporadic #Alzheimers.

    @ToxGenSolutions BV disembarks on its data-driven journey towards novel tools and treatments for improving the quality of life of patients with sporadic #Alzheimers.

    February 09, 2018 @TozGenSolutions and its partners in the project #Herinneringen (''Memories'') have disembarked on their journey towards a technology platform for 1) development of a non-invasive method for early #diagnosis, 2) identification of novel #drug targets and 3) improved #drugdevelopment approaches. The building of the platform is data-driven (as opposed to the current hypothesis-driven strategies) and based on adverse outcome pathways (#AOP) identified using #nonanimal genomics-based methods and involving cell models, and matched human clinical samples and human cohorts. The overall objective is to break the current deadlock and to provide patients with sporadic #Alzheimers with novel tools and treatments that improve their quality of life. Every partner in the consortium (icometrix, Katholieke Universiteit Leuven, reMYND, ToxGenSolutions, Universiteit Antwerpen, Universiteit Maastricht) is based in Flanders and the Southern Netherlands and is a leader in their professional field. Bundling these strengths and the resulting synergy will serve as a great stimulus for targeted innovation. The total budget for “Memories” is €2,476,613.03. The project will run from January 1, 2018 up to and including December 31, 2020. The budget is provided by public organizations, such as Interreg. Vlaanderen-Nederland, the Dutch Ministry of Economic Affaires, the Flemish Region and Provinces.
  • ToxGenSolutions BV prepares for tackling a growing health problem: dementia

    #ToxGenSolutions BV is looking for funding of a cross-borders private (SMEs)/public project aiming at expanding our understanding of the early events of neurodegenerative diseases, e.g. #Alzheimers. One deliverable is a novel tool for early diagnosis of neurodegenerative diseases, e.g. Alzheimers. The project will focus on the #animalfree identification of the molecular and cellular mechanisms triggered by a selection of relevant environmental chemicals and pharmaceuticals in human induced pluripotent stem cells (#iPSC), and iPSC-derived human brain tissue, with and without genetic mutations observed in Alzheimers patients. Early diagnosis is the first step towards improved therapies capable of suppressing disease progression. It is also anticipated that this project allows for the identification of new targets for drug development, having an additional positive impact on the quality of therapy.
  • Saxocon ApS (DK) and ToxGenSolutions BV (NL) join forces to improve #animalfree product development

    (Q)SAR modeling is currently used to identify chemicals having desired physico-chemical/structural characteristics (e.g. new leads for drug development), or exhibiting characteristics known to exert adverse effects in humans (e.g. hazard identification and safety testing). It is not well established yet how well these (Q)SAR models discriminate chemicals with similar physico-chemical/structural characteristics but different in vivo outcome. This is a problem e.g. when in vivo animal models incorrectly indicate unsatisfactory efficacy or toxicity. By combining physico-chemical/structural analysis [Saxocon ApS (DK)] and biological pathway analysis of exposed human cells and tissue [ToxGenSolutions BV (NL)], both companies are convinced that they can offer costumers a novel quantitative #animalfree systems biology approach for efficacy/toxicity assessment, and more accurate human health and safety, where current in vivo animal models fail.
  • Application nr. 14/028.308 'In vitro method for determining immunotoxicity of a compound' is now also allowed for issuance as a patent in the USA

    Main claim: An in vitro method of detecting altered expression of at least one marker gene in response to a compound, the method comprising: - exposing a nucleated cell to the compound; - detecting the level of the at least one marker gene expressed by the nucleated cell after exposure to the compound; and - detecting altered expression of the at least one marker gene if the level of expression of the at least one marker gene is above or below a predetermined reference value for the level of expression of the at least one marker gene; - wherein the at least one marker gene is selected from the group consisting of ABCA1, CHAC1, CRIM1 and HMGCS1; and - wherein the immunotoxicity of the compound is not known.
  • EPO has granted a European patent on the basis of the application 12 184 575.4-1402 ''In vitro method for determining immunotoxicity of a compound''

    Claim 1: In vitro method for determining whether a compound is immunotoxic wherein the expression level of at least one marker gene is determined in a sample obtained from a Jurkat cell culture in vitro, which is exposed to the compound in the in vitro culture, wherein the marker gene is ABCA1, and wherein it is concluded that the compound is immunotoxic if the expression level of the ABCA1 marker gene is below or above a predetermined reference value. Claim 2: Method according to claim 1 wherein the expression level of three additional marker genes is determined in the sample obtained from the Jurkat cell cultured in vitro wherein it is concluded that the compound is immunotoxic if the expression level of at least one additional marker gene is below or above a predetermined reference value wherein the additional marker genes are CHAC1, CRIM1 and HMGCS1.
  • Banner03

How does it work

A VIRTUAL GENERIC GENOMICS-BASED PLATFORM THAT PROVIDES ANSWERS TO YOUR QUESTIONS ABOUT SAFETY AND EFFICACY OF YOUR PRODUCTS.

 

Next-generation tools

  • A systems-based technology platform for profiling the positive as well as negative impact of your product on biological response and human health at realistic concentrations and under relevant exposure regimes.
  • Our toolbox contains a breadth of technologies, systems, and pathways of toxicity and common nodes of toxicity developed by the Netherlands ToxicoGenomics Center (2008-2013).
  • The ToxGenSolutions toolbox is also useful for the identification of new opportunities for product development
  • The ToxGenSolutions toolbox is flexible, faster than traditional methods, more economical and more relevant for human safety and health.

Front-edge technologies

  • ToxGenSolutions products are proprietary mechanism-based gene signatures for identification and classification of toxicants during screening, product development and safety assessment.
  • ToxGenSolutions provides a cutting-edge patchwork of test methods required for modern testing and assessment of compounds and products.
  • ToxGenSolutions builds on a virtual generic platform of leading test and technology developers providing novel technologies addressing key events in outcome pathways.

Focus on your needs

  • ToxGenSolutions develops testing and assessment strategies for, and with, you to assure optimal coverage of your needs.
  • ToxGenSolutions develops strategies considering the nature of the test substance, the intended application, likely exposure routes, product development status and legislation.
  • Banner4

For a safer future

THE WORKING HYPOTHESIS IS THAT THE COMBINATION OF EXPERTISE AND TECHNOLOGY FROM DIFFERENT DISCIPLINES WILL PROVIDE THE UNDERSTANDING OF HOW CHEMICALS INTERACT WITH BIOLOGICAL SYSTEMS THAT IS REQUIRED TO IMPROVE HUMAN SAFETY AND HEALTH.

Animal-free chemical safety assessment
Aligning the 3Rs with new paradigms in the safety assessment of chemicals
Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment
  • Banner4

Still on the table

Improving #animalfree testing and assessment by combining physico-chemical/structural analysis and biological pathway analysis of exposed human cells and tissuel.

(Q)SAR modeling is currently used to identify chemicals that are most likely to become a product,by having desired physico-chemical/structural characteristics (e.g. new leads for drug development), and by not exhibiting characteristics known to exert adverse effects in humans (e.g. hazard identification and safety testing). It is currently not well established how well current (Q)SAR models discriminate chemicals with similar physico-chemical/structural characteristics but different in vivo outcome. This is a problem e.g. when in vivo animal models incorrectly indicate unsatisfactory efficacy or toxicity. ToxGenSolutions BV envisages a novel quantitative systems biology approach for toxicity assessment linking physico-chemical characteristics of test compounds ((Q)SAR) with biological impact on cells/tissues, providing more accurate human health and safety where in vivo animal models fail.

A novel therapy for slowing down the progression of neurodegenerative diseases through a better understanding of the impact of environmental chemicals on neurodegeneration induction.

The incidence of neurodegenerative diseases (e.g. Alzheimer’s, Parkinson, multiple and amyotrophic lateral sclerose) is globally on the rise, and the increasing number of patients is challenging the existing medical care ressources. While these diseases are driven by genetics, there is also an important environmental input. Despite decennia of intensive research early diagnose and effective therapy of these diseases is not yet possible. There are two important hurtles: 1. The underlying mechanisms of induction of neurodegeneration in humans are still not sufficiently understood; 2. The blood-brain barrier allows only chemicals with specific physicochemical charactereistics to enter the brain. ToxGenSolutions BV envisages a project addressing the mechanistic aspects (Hurtle 1). -Omics approaches based on human stemcells and tissues are anticipated (i) to provide better and more relevant knowldege about the mechanisms affected by environmental factors and driving the induction of neurodegenerative diseases in humans, and (ii) to allow for the identification of human-relevant early biomarkers. Thus, the acquired knowledge offers new opportunities for the development of novel more accurate methods for early diagnosis of disease induction. In addition, alternative targets for novel anti-neurodegenerative drugs are anticipated to emerge from this project.